Manning & Napier Group's NVO Position Overview
Manning & Napier Group (via Manning & Napier Advisors LLC) currently holds 166,932 shares of Novo Nordisk A/S (NVO) worth $8.55 M, representing 0.11% of the portfolio. First purchased in 2025-Q2, this short-term holding has been held for 3 quarters.
Based on 13F filings, Manning & Napier Group has maintained this position in NVO for several quarters, showing initial confidence in the investment. Largest reduction occurred in Q3 2025, reducing 21,973 shares.
Analysis based on 13F filings available since 2013 Q2
Manning & Napier Group's Novo Nordisk A/S (NVO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Novo Nordisk A/S (NVO) Trades by Manning & Napier Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -15,269 | Reduce 8.38% | 166,932 | $51.22 |
| Q3 2025 | -21,973 | Reduce 10.76% | 182,201 | $55.50 |
| Q2 2025 | +204,174 | New Buy | 204,174 | $69.02 |
Manning & Napier Group's Novo Nordisk A/S Investment FAQs
Manning & Napier Group first purchased Novo Nordisk A/S (NVO) in Q2 2025, acquiring 204,174 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Manning & Napier Group has held Novo Nordisk A/S (NVO) for 3 quarters since Q2 2025.
Manning & Napier Group's largest addition to Novo Nordisk A/S (NVO) was in Q2 2025, adding 204,174 shares worth $14.09 M.
According to the latest 13F filing for Q4 2025, Manning & Napier Group's firm, Manning & Napier Advisors LLC, owns 166,932 shares of Novo Nordisk A/S (NVO), valued at approximately $8.55 M.
As of the Q4 2025 filing, Novo Nordisk A/S (NVO) represents approximately 0.11% of Manning & Napier Group's publicly disclosed stock portfolio, making it one of their key holdings.
Manning & Napier Group's peak holding in Novo Nordisk A/S (NVO) was 204,174 shares, as reported at the end of Q2 2025.